IDH1 and glioblastoma: In epithelioid GBM (with markers of the BRAF‐V600E and TERT C228T promoter mutations and the absence of IDH1 and IDH2 mutations), CSF-1R is also detected broadly on epithelioid GBM cells and combination of inhibiting BRAF-V600E and BLZ945 reduces cell viabilities [308].